What do systematic reviews say?

Antidepressants vs any complementary medicine

The review found no eligible studies for this question.

• Antidepressant treatment for postnatal depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Paroxetine vs placebo

It is very uncertain whether paroxetine changes treatment acceptability compared with placebo (very low certainty).

• Pharmacotherapy for anxiety and comorbid alcohol use disorders 2015 · Cochrane Headline outcomes only
  RR 3.29 [0.14, 76.33]
  2 studies · 57 participants
  Very low

Exercise vs pharmacological treatments

• Exercise for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 278 participants
  Moderate

Exercise vs control

• Exercise for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  29 studies · 1363 participants
  Moderate

Exercise vs psychological treatment

• Exercise for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 172 participants
  Moderate

Mindfulness‐based 'third wave' cognitive and behavioural therapies vs ALL OTHER PSYCHOLOGICAL THERAPIES

It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes treatment acceptability at compared with other psychological therapies (very low certainty).

• 'Third wave' cognitive and behavioural therapies versus other psychological therapies for depression 2013 · Cochrane Headline outcomes only
  RR 1.07 [0.1, 11.23]
  2 studies · 56 participants
  Very low

Ketamine vs midazolam

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Very low

Memantine vs placebo

Memantine showed no clear difference in acceptability: total dropouts compared with placebo (low certainty).

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  OR 0.77 [0.45, 1.31]
  2 studies · 261 participants
  Low

Cytidine vs placebo

It is very uncertain whether cytidine changes acceptability: total dropouts compared with placebo (very low certainty).

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  OR 0.94 [0.12, 7.52]
  1 study · 35 participants
  Very low

Riluzole vs placebo

It is very uncertain whether riluzole changes acceptability: total dropouts compared with placebo (very low certainty).

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  OR 2 [0.31, 12.84]
  1 study · 19 participants
  Very low

Ketamine vs placebo

It is very uncertain whether ketamine changes acceptability: total dropouts compared with placebo (very low certainty).

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  OR 3.48 [0.56, 21.74]
  2 studies · 33 participants
  Very low

Lithium vs valproate

Lithium showed no clear difference in acceptability: total withdrawals compared with valproate (high certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.2 [0.86, 1.69]
  5 studies · 629 participants
  High

Lithium vs lamotrigine

It is very uncertain whether lithium changes acceptability: total withdrawals compared with lamotrigine (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.8 [0.5, 1.29]
  3 studies · 303 participants
  Very low

Lithium vs carbamazepine

Lithium showed no clear difference in acceptability: total withdrawals compared with carbamazepine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.2 [0.02, 1.94]
  1 study · 34 participants
  Low

Lithium vs QUETIAPINE

It is very uncertain whether lithium changes acceptability: total withdrawals compared with quetiapine (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.38 [0.83, 2.28]
  2 studies · 359 participants
  Very low

Lithium vs OLANZAPINE

Lithium may leads to higher acceptability: total withdrawals compared with olanzapine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 2.6 [1.13, 5.99]
  3 studies · 210 participants
  Low

Lithium vs placebo

Lithium showed no clear difference in acceptability: total withdrawals compared with placebo (moderate certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.76 [0.46, 1.25]
  7 studies · 1353 participants
  Moderate

Lithium vs chlorpromazine

Lithium showed no clear difference in acceptability: total withdrawals compared with chlorpromazine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.75 [0.92, 3.31]
  2 studies · 262 participants
  Low

Lithium vs haloperidol

It is very uncertain whether lithium changes acceptability: total withdrawals compared with haloperidol (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.29 [0.03, 3.12]
  1 study · 30 participants
  Very low

Lithium vs Zuclopenthixol (Cis Z/Trans E isomer)

It is very uncertain whether lithium changes acceptability: total withdrawals compared with zuclopenthixol (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.78 [0.17, 3.49]
  1 study · 28 participants
  Very low